Royalty Pharma Partners with Biogen to Develop Litifilimab
Shots:
- Royalty Pharma & Biogen have entered into an agreement for the clinical development of litifilimab in SLE & CLE
- As per the agreement, Biogen will receive ~$250M R&D funding over 6 quarters to support the development, whereas Royalty Pharma is entitled to receive regulatory milestones & mid-single digit royalties on global sales
- Litifilimab (anti-BDCA2 mAb) is being investigated in P-III trials for both SLE & CLE with results expected in 2026-2027, while PoC data of distinct MoA & safety is published in The NEJM
Ref: Royalty Pharma | Image: Royalty Pharma & Biogen
Related News:- Eisai and Biogen Reports the CHMP’s Positive Opinion of Lecanemab to Treat Early Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com